For women with primary progressive multiple sclerosis, could Roche’s best selling drug be doing more harm than good?

Investigation explores how an $80,000 a year drug was approved for primary progressive form of MS despite concerns over its safety and effectiveness  The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche’s top-selling drug ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (PPMS) - a form of ...